[HTML][HTML] Seropositivity is associated with insulin resistance in patients with early inflammatory polyarthritis: results from the Norfolk Arthritis Register (NOAR): an …

H Mirjafari, TM Farragher, SMM Verstappen… - Arthritis research & …, 2011 - Springer
Introduction Cardiovascular disease (CVD) is the leading cause of death in patients with
inflammatory polyarthritis (IP), especially in seropositive disease. In established rheumatoid …

Characteristics of antiphospholipid antibody positive patients in antiphospholipid syndrome alliance for clinical trials and international networking

E Sevim, D Zisa, D Andrade, S Sciascia… - Arthritis Care & …, 2022 - discovery.ucl.ac.uk
OBJECTIVE: To describe baseline characteristics of antiphospholipid antibody (aPL)-
positive patients, overall and by clinical and laboratory subtypes, enrolled in an international …

[HTML][HTML] Different properties of ACPA and IgM-RF derived from a large dataset: further evidence of two distinct autoantibody systems

J Ursum, WH Bos, RJ van de Stadt… - Arthritis research & …, 2009 - Springer
Introduction The aim of this study was to examine seroconversion and the relationship with
age and inflammation of autoantibodies in a large group of patients attending an outpatient …

Auto-antibodies do not influence development of atherosclerotic plaques in rheumatoid arthritis

I Pereira, I Laurindo, R Burlingame, L Anjos, V Viana… - Joint Bone Spine, 2008 - Elsevier
BACKGROUND: Many questions remain unanswered about premature atherosclerosis in
rheumatoid arthritis (RA). Besides inflammation, some studies have suggested the role of …

The prevalence and clinical significance of antiphospholipid antibodies in rheumatoid arthritis

E Olech, JT Merrill - Current rheumatology reports, 2006 - Springer
Published data were reviewed to evaluate the occurrence of antiphospholipid antibodies
(aPL) in rheumatoid arthritis (RA) patients and to investigate their clinical relevance in this …

[HTML][HTML] Association between antibodies to carbamylated proteins and subclinical atherosclerosis in rheumatoid arthritis patients

FR Spinelli, A Pecani, F Ciciarello, T Colasanti… - BMC musculoskeletal …, 2017 - Springer
Background Rheumatoid arthritis (RA) patients carry a high risk of cardiovascular morbidity
and mortality. The excess of cardiovascular disease cannot be entirely explained by …

Fluctuation of Anti–Domain 1 and Anti–β2‐Glycoprotein I Antibody Titers Over Time in Patients With Persistently Positive Antiphospholipid Antibodies

CB Chighizola, F Pregnolato, D Andrade… - Arthritis & …, 2023 - Wiley Online Library
Objective The present study was undertaken to longitudinally evaluate titers of antibodies
against β2‐glycoprotein I (anti‐β2GPI) and domain 1 (anti‐D1), to identify predictors of …

[引用][C] New approaches to prevention of thrombosis in the antiphospholipid syndrome: hopes, trials, and tribulations

RAS Roubey - Arthritis & Rheumatism, 2003 - Wiley Online Library
Prevention of thrombosis in patients with the antiphospholipid syndrome (APS) remains a
vexing clinical problem. On the one hand, current treatment recommendations are …

Association of inflammatory mediators with premature atherosclerosis in rheumatoid arthritis and healthy controls: comment on the article by Rho et al

P Welsh, N Sattar, M Peters - Arthritis care & research, 2010 - Wiley Online Library
We read with interest the article by Rho et al, published recently in Arthritis Care & Research
(1), reporting that inflammatory markers interleukin-6 (IL-6), tumor necrosis factor α (TNFα) …

[HTML][HTML] Levels of anti-citrullinated protein antibodies and IgM rheumatoid factor are not associated with outcome in early arthritis patients: a cohort study

J Ursum, WH Bos, N van Dillen, BAC Dijkmans… - Arthritis research & …, 2010 - Springer
Introduction To investigate whether baseline levels of anti-citrullinated protein antibody
(ACPA) or IgM rheumatoid factor (IgM-RF) and changes in the year thereafter are associated …